The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
How to treat older and frail patients with CLL?
Featured:
Ulrich Jäger
Grzegorz Nowakowski
Martin Dreyling
Stefano Luminari
Gilles Salles
Francesc Bosch
Astrid Pavlovsky
Judith TrotmanDuring the Lymphoma Hub Steering Committee meeting, Francesc Bosch chaired a discussion on, How to treat older and frail patients with CLL?
How to treat older and frail patients with CLL?
This discussion also featured Gilles Salles, Grzegorz Nowakowski, Martin Dreyling, Judith Trotman, Stefano Luminari, Ulrich Jӓger, and Astrid Pavlovsky. The panel discussed:
- the comorbidity influence on BTK inhibitors and treatment schedule interruption;
- patient preferences in the older and frail population (75–90 years);
- sequencing of treatments in older and frail patients with CLL; and
- specific comorbidities observed in older and frail patients with CLL.